Motiva Flora® Aesthetic Breast Recon® Clinical Study
← catalyst calendarSponsored by Establishment Labs (industry) · ESTA — their whole pipeline →. With NAMSA.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
66estimated
Sites
4
Countries
Belgium, Colombia, Costa Rica +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-18 | actual | When the study began enrolling |
| Primary completion | Apr 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mammaplasty
- Breast Cancer
- Poland Syndrome
Intervention
- Device: Motiva Flora® Tissue Expander — also filed as Motiva Implants Ergonomix2® Sterile Silicone Breast Implants
Primary outcome
what the primary-completion date above is the date OFTotal adverse envent rate
measured 46 months
Permalink · ESTA's whole pipeline · Catalyst calendar · Every registered study · What changed